Works matching IS 00302414 AND DT 2022 AND VI 100 AND IP 2

Results: 8

Front & Back Matter.

Published in:: Oncology, 2022, v. 100, n. 2, p. 1, doi. 10.1159/000522299
Publication type:: Article

Post-Progression Survival Highly Influences Overall Survival in Driver Gene Mutation/Translocation Negative or Unknown Type of Non-Small Cell Lung Cancer.

Published in:

Oncology, 2022, v. 100, n. 2, p. 89, doi. 10.1159/000521141

By:

Imai, Hisao;
Onozato, Ryoichi;
Kaira, Kyoichi;
Kawashima, Sayaka;
Masubuchi, Ken;
Tajima, Kohei;
Minato, Koichi

Publication type:

Article

Prognoses in Pathologically Confirmed T1 Lower Rectal Cancer Patients with or without Preoperative Therapy: An Analysis Using the Surveillance, Epidemiology, and End Results Database.

Published in:

Oncology, 2022, v. 100, n. 2, p. 82, doi. 10.1159/000521033

By:

Taira, Tetsuro;
Nozawa, Hiroaki;
Kawai, Kazushige;
Sasaki, Kazuhito;
Murono, Koji;
Emoto, Shigenobu;
Kishikawa, Junko;
Ozawa, Tsuyoshi;
Yokoyama, Yuichiro;
Abe, Shinya;
Nagai, Yuzo;
Anzai, Hiroyuki;
Sonoda, Hirofumi;
Ishihara, Soichiro

Publication type:

Article

Variations in Radioiodine Therapy in Europe: Decision-Making after Total Thyroidectomy.

Published in:

Oncology, 2022, v. 100, n. 2, p. 74, doi. 10.1159/000520938

By:

Forrer, Flavio;
Fischer, Galina Farina;
Maas, Ole;
Giovanella, Luca;
Hoffmann, Martha;
Iakovou, Ioannis;
Luster, Markus;
Mihailovic, Jasna;
Petranovic Ovčariček, Petra;
Vrachimis, Alexis;
Zerdoud, Slimane;
Putora, Paul Martin

Publication type:

Article

Body Mass Index, Sarcopenia, and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma.

Published in:

Oncology, 2022, v. 100, n. 2, p. 114, doi. 10.1159/000520833

By:

Herrmann, Tressie;
Mione, Cécile;
Montoriol, Pierre-François;
Molnar, Ioana;
Ginzac, Angeline;
Durando, Xavier;
Mahammedi, Hakim

Publication type:

Article

Fanconi Anemia Complementation Group E, a DNA Repair-Related Gene, Is a Potential Marker of Poor Prognosis in Hepatocellular Carcinoma.

Published in:

Oncology, 2022, v. 100, n. 2, p. 101, doi. 10.1159/000520582

By:

Takahashi, Junichi;
Masuda, Takaaki;
Kitagawa, Akihiro;
Tobo, Taro;
Nakano, Yusuke;
Abe, Tadashi;
Ando, Yuki;
Kosai, Keisuke;
Kobayashi, Yuta;
Matsumoto, Yoshihiro;
Yoshizumi, Tomoharu;
Mori, Masaki;
Mimori, Koshi

Publication type:

Article

Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.

Published in:

Oncology, 2022, v. 100, n. 2, p. 65, doi. 10.1159/000520292

By:

Hiraoka, Atsushi;
Kumada, Takashi;
Kariyama, Kazuya;
Toyoda, Hidenori;
Yasuda, Satoshi;
Tsuji, Kunihiko;
Hatanaka, Takeshi;
Kakizaki, Satoru;
Naganuma, Atsushi;
Ishikawa, Toru;
Tada, Toshifumi;
Takaguchi, Koichi;
Itobayashi, Ei;
Shimada, Noritomo;
Shibata, Hiroshi;
Tanaka, Takaaki;
Tsutsui, Akemi;
Nagano, Takuya;
Imai, Michitaka;
Nakamura, Shinichiro

Publication type:

Article

Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study.

Published in:

Oncology, 2022, v. 100, n. 2, p. 124, doi. 10.1159/000519767

By:

Briggs, Andrew;
Paracha, Noman;
Rosettie, Katherine;
Upton, Alexander;
Bokemeyer, Carsten;
Lassen, Ulrik;
Sullivan, Sean D.

Publication type:

Article